257 related articles for article (PubMed ID: 30381394)
1. Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate.
Dexter JP; Ward PS; Dasgupta T; Hosios AM; Gunawardena J; Vander Heiden MG
J Biol Chem; 2018 Dec; 293(52):20051-20061. PubMed ID: 30381394
[TBL] [Abstract][Full Text] [Related]
2. Low pH Facilitates Heterodimerization of Mutant Isocitrate Dehydrogenase IDH1-R132H and Promotes Production of 2-Hydroxyglutarate.
Sesanto R; Kuehn JF; Barber DL; White KA
Biochemistry; 2021 Jun; 60(25):1983-1994. PubMed ID: 34143606
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma.
van Lith SA; Navis AC; Lenting K; Verrijp K; Schepens JT; Hendriks WJ; Schubert NA; Venselaar H; Wevers RA; van Rooij A; Wesseling P; Molenaar RJ; van Noorden CJ; Pusch S; Tops B; Leenders WP
Sci Rep; 2016 Jul; 6():30486. PubMed ID: 27460417
[TBL] [Abstract][Full Text] [Related]
4. Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer.
Brooks E; Wu X; Hanel A; Nguyen S; Wang J; Zhang JH; Harrison A; Zhang W
J Biomol Screen; 2014 Sep; 19(8):1193-200. PubMed ID: 24980596
[TBL] [Abstract][Full Text] [Related]
5. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.
Davis MI; Gross S; Shen M; Straley KS; Pragani R; Lea WA; Popovici-Muller J; DeLaBarre B; Artin E; Thorne N; Auld DS; Li Z; Dang L; Boxer MB; Simeonov A
J Biol Chem; 2014 May; 289(20):13717-25. PubMed ID: 24668804
[TBL] [Abstract][Full Text] [Related]
6. Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer.
Chen D; Xia S; Wang M; Lin R; Li Y; Mao H; Aguiar M; Famulare CA; Shih AH; Brennan CW; Gao X; Pan Y; Liu S; Fan J; Jin L; Song L; Zhou A; Mukherjee J; Pieper RO; Mishra A; Peng J; Arellano M; Blum WG; Lonial S; Boggon TJ; Levine RL; Chen J
Cancer Discov; 2019 Jun; 9(6):756-777. PubMed ID: 30862724
[TBL] [Abstract][Full Text] [Related]
7. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.
Ward PS; Lu C; Cross JR; Abdel-Wahab O; Levine RL; Schwartz GK; Thompson CB
J Biol Chem; 2013 Feb; 288(6):3804-15. PubMed ID: 23264629
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency.
Avellaneda Matteo D; Grunseth AJ; Gonzalez ER; Anselmo SL; Kennedy MA; Moman P; Scott DA; Hoang A; Sohl CD
J Biol Chem; 2017 May; 292(19):7971-7983. PubMed ID: 28330869
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1).
Kang CH; Choi SU; Son YH; Lee HK; Jeong HG; Yun CS; Ahn S; Park CH
Anticancer Res; 2020 Sep; 40(9):4929-4935. PubMed ID: 32878781
[TBL] [Abstract][Full Text] [Related]
10. Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation.
Leonardi R; Subramanian C; Jackowski S; Rock CO
J Biol Chem; 2012 Apr; 287(18):14615-20. PubMed ID: 22442146
[TBL] [Abstract][Full Text] [Related]
11. Mutant IDH1 enhances the production of 2-hydroxyglutarate due to its kinetic mechanism.
Rendina AR; Pietrak B; Smallwood A; Zhao H; Qi H; Quinn C; Adams ND; Concha N; Duraiswami C; Thrall SH; Sweitzer S; Schwartz B
Biochemistry; 2013 Jul; 52(26):4563-77. PubMed ID: 23731180
[TBL] [Abstract][Full Text] [Related]
12. Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.
Ohka F; Ito M; Ranjit M; Senga T; Motomura A; Motomura K; Saito K; Kato K; Kato Y; Wakabayashi T; Soga T; Natsume A
Tumour Biol; 2014 Jun; 35(6):5911-20. PubMed ID: 24590270
[TBL] [Abstract][Full Text] [Related]
13. Novel Insights for Inhibiting Mutant Heterodimer IDH1
Juritz EI; Bascur JP; Almonacid DE; González-Nilo FD
Mol Diagn Ther; 2018 Jun; 22(3):369-380. PubMed ID: 29651790
[TBL] [Abstract][Full Text] [Related]
14. Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin.
Biedermann J; Preussler M; Conde M; Peitzsch M; Richter S; Wiedemuth R; Abou-El-Ardat K; Krüger A; Meinhardt M; Schackert G; Leenders WP; Herold-Mende C; Niclou SP; Bjerkvig R; Eisenhofer G; Temme A; Seifert M; Kunz-Schughart LA; Schröck E; Klink B
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31888244
[TBL] [Abstract][Full Text] [Related]
15. Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG.
Navis AC; Niclou SP; Fack F; Stieber D; van Lith S; Verrijp K; Wright A; Stauber J; Tops B; Otte-Holler I; Wevers RA; van Rooij A; Pusch S; von Deimling A; Tigchelaar W; van Noorden CJ; Wesseling P; Leenders WP
Acta Neuropathol Commun; 2013 May; 1():18. PubMed ID: 24252742
[TBL] [Abstract][Full Text] [Related]
16. Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT).
Grassian AR; Lin F; Barrett R; Liu Y; Jiang W; Korpal M; Astley H; Gitterman D; Henley T; Howes R; Levell J; Korn JM; Pagliarini R
J Biol Chem; 2012 Dec; 287(50):42180-94. PubMed ID: 23038259
[TBL] [Abstract][Full Text] [Related]
17. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
Gross S; Cairns RA; Minden MD; Driggers EM; Bittinger MA; Jang HG; Sasaki M; Jin S; Schenkein DP; Su SM; Dang L; Fantin VR; Mak TW
J Exp Med; 2010 Feb; 207(2):339-44. PubMed ID: 20142433
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Sells.
Badur MG; Muthusamy T; Parker SJ; Ma S; McBrayer SK; Cordes T; Magana JH; Guan KL; Metallo CM
Cell Rep; 2018 Oct; 25(4):1018-1026.e4. PubMed ID: 30355481
[TBL] [Abstract][Full Text] [Related]
19. TOF-SIMS analysis of an isocitrate dehydrogenase 1 mutation-associated oncometabolite in cancer cells.
Park J; Na HK; Shon HK; Son HY; Huh YM; Lee SW; Lee TG
Biointerphases; 2018 Jan; 13(3):03B404. PubMed ID: 29382206
[TBL] [Abstract][Full Text] [Related]
20. Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.
Wen H; Cho HR; Yun T; Kim H; Park CK; Lee SH; Choi SH; Park S
J Neurochem; 2015 Jan; 132(2):183-93. PubMed ID: 25251602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
